CRYOPORT INC
NASDAQ: CYRX (CryoPort, Inc.)
Last update: 13 hours ago19.05
-0.50 (-2.56%)
| Previous Close | 19.55 |
| Volume | 814,782 |
| Avg. Volume (3M) | 843,800 |
| Market Cap | 964,865,344 |
| Price / Earnings (Forward) | 73.27 |
| Price / Sales | 4.97 |
| Price / Book | 2.22 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | -21.46% |
| Operating Margin (TTM) | -14.40% |
| Diluted EPS (TTM) | -0.900 |
| Quarterly Revenue Growth (YOY) | 13.50% |
| Total Debt/Equity (MRQ) | 47.88% |
| Current Ratio (MRQ) | 2.04 |
| Operating Cash Flow (TTM) | 11.00 M |
| Levered Free Cash Flow (TTM) | -10.91 M |
| Return on Assets (TTM) | -2.27% |
| Return on Equity (TTM) | -7.44% |
News Mood
-
Does Raised Revenue Guidance Change The Bull Case For Cryoport (CYRX)?
12 Nov, 12:10AM
-
Why Cryoport (CYRX) Shares Climbed After Its Latest Update?
10 Nov, 3:14PM
-
What Comes Next For Cryoport After A 100% Gain
09 Nov, 2:06PM
AIStockmoo Score
| Value 30% | -2.5 |
| Earns below its cost of capital. Returns on capital falling. info | |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 3.1 |
| Uptrend over the past year. Trading near its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 0.3 |
| Insiders net selling recently. info | |
| Institutions net +2.15% of shares in their latest 13F filings: 94 holders increased, 89 decreased (quarter to 30 Sep 2026). info | |
| Short interest +28.1% from 31 Aug to 30 Oct 2026, 4.1 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Earnings per share have gone up and down. Made a loss in recent years. info | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Price is near resistance. info | |
| Final Score | 0.22 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Integrated Freight & Logistics (US) | Mixed | Bullish |
| Integrated Freight & Logistics (Global) | Mixed | Bullish | |
| Stock | CryoPort, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| CYRX | 965 M | - | - | 2.22 | 0.2 |
| FWRD | 549 M | - | - | 5.97 | -1.0 |
| SFWL | 27 M | - | 2.25 | 0.190 | -1.3 |
| SLGB | 6 M | - | - | 0.390 | -2.8 |
| SGLY | 2 M | - | 0.034 | 0.040 | -2.2 |
| CTNT | - | - | - | 0.030 | -2.3 |
Select this tab to load the latest available analysis.
|
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas. |
|
| Sector | Industrials |
| Industry | Integrated Freight & Logistics |
| Investment Style | Small Value |
| % Held by Insiders | 3.83% |
| % Held by Institutions | 95.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 30 Sep 2026 | 2,418,947 |
| Fred Alger Management, Llc | 30 Sep 2026 | 1,690,723 |
| Mak Capital One Llc | 30 Sep 2026 | 1,074,631 |
| Silvercrest Asset Management Group Llc | 30 Sep 2026 | 781,741 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HANCOCK DANIEL M | - | 20.47 | -74,379 | -1,522,538 |
| SAWICKI MARK W | - | 20.74 | -10,000 | -207,400 |
| Aggregate Net Quantity | -84,379 | |||
| Aggregate Net Value ($) | -1,729,938 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 20.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SAWICKI MARK W | Officer | 10 Nov 2026 | Sell (-) | 10,000 | 20.74 | 207,400 |
| HANCOCK DANIEL M | Director | 09 Nov 2026 | Sell (-) | 74,379 | 20.47 | 1,522,538 |
| HANCOCK DANIEL M | Director | 09 Nov 2026 | Option execute | 74,379 | - | - |
Institutions
Institutional ownership: 95.44%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 94 | 5,218,816 |
| Decreased | 89 | 4,937,196 |
| New | 30 | 1,449,620 |
| Sold out | 18 | 632,376 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 3,477,459 | 4.1 |
| 15 Oct 2026 | 2,532,755 | 3.1 |
| 30 Sep 2026 | 2,362,636 | 3.4 |
| 15 Sep 2026 | 2,786,514 | 5.8 |
| 31 Aug 2026 | 2,713,665 | 4.9 |
| 14 Aug 2026 | 2,515,480 | 4.6 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Cryoport (CYRX) Stock Looks Fully Priced Following Its 129% Rebound
Cryoport has delivered a sharp rebound in its share price, which naturally puts the focus on whether the current valuation can be grounded in its sales rather than just recent momentum. With a stock that has moved this far, this fast, the question is how well the revenue base supports where the… |
| 12 Nov 2026 | Yahoo Finance |
Does Raised Revenue Guidance Change The Bull Case For Cryoport (CYRX)?
Cryoport reported third quarter 2026 revenue of US$50.22 million compared to US$44.23 million a year earlier, with a wider net loss of US$10.85 million and basic loss per share of US$0.25. The business lifted full year 2026 revenue guidance to a range of US$197 million to US$199 million… |
| 10 Nov 2026 | Yahoo Finance |
Why Cryoport (CYRX) Shares Climbed After Its Latest Update?
Cryoport (CYRX) has become a talking point after its third quarter 2026 report, which paired higher revenue with a wider loss and an increase in full year sales guidance to US$197 million to US$199 million. The guidance hike has landed in a market that was already re-rating Cryoport, with the share… |
| 09 Nov 2026 | Yahoo Finance |
What Comes Next For Cryoport After A 100% Gain
If Cryoport was on your watchlist rather than in your portfolio over 2026, the outcome may feel like a missed shot. For Cryoport shareholders, the return from the start of the year was 99.8%, including dividends. That kind of move invites a hard question. Back on 1 January, when analysts were split… |
| 06 Nov 2026 | Yahoo Finance |
Cryoport, Inc. Q3 2026 Earnings Call Summary
Moby summary of Cryoport, Inc.'s Q3 2026 earnings call… |
| 06 Nov 2026 | Yahoo Finance |
Cryoport (CYRX) Q3 2026 Earnings Call Transcript
Services growth and a raised outlook headline a strong cell therapy logistics quarter. |
| 06 Nov 2026 | Yahoo Finance |
CryoPort Inc (CYRX) (Q3 2026) Earnings Call Highlights: Record Clinical Pipeline and Positive ...
CryoPort Inc (CYRX) lifted its full-year 2026 revenue outlook to $197-$199 million after posting 14% growth and a second straight quarter of positive adjusted EBITDA. |
| 06 Nov 2026 | Yahoo Finance |
CryoPort Q3 Earnings Call Highlights
CryoPort (NASDAQ:CYRX) raised its full-year 2026 revenue outlook after reporting third-quarter revenue growth of 14%, supported by demand for its cell and gene therapy services and cryogenic products. The company reported revenue of $50.2 million and adjusted earnings before interest, taxes, deprec… |
| 05 Nov 2026 | Yahoo Finance |
CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates
CryoPort (CYRX) delivered earnings and revenue surprises of -31.58% and +3.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 05 Nov 2026 | Yahoo Finance |
Cryoport Reports Third Quarter 2026 Financial Results
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026… |
| 04 Nov 2026 | Yahoo Finance |
Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates
Cencora (COR) delivered earnings and revenue surprises of +2.19% and +0.22%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 22 Oct 2026 | Yahoo Finance |
Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2026 on Thursday… |
| 01 Oct 2026 | Yahoo Finance |
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year. |
| 24 Aug 2026 | Yahoo Finance |
Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions
The latest analyst work on Cryoport points to a higher blended fair value estimate, with price targets moving from US$17.06 to US$19.33, about a 13% uplift in the modeled target level. That shift lines up with more constructive Street commentary, as several bullish analysts highlight Cryoport’s… |
| Show more | ||
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |